Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection (DE-17-17)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04253366
Recruitment Status : Not yet recruiting
First Posted : February 5, 2020
Last Update Posted : March 24, 2020
Sponsor:
Information provided by (Responsible Party):
Umbria Bioengineering Technologies

Brief Summary:
This is a multicentric, single arm, prospective, stratified by breast density clinical investigation using Mammowave that is a device, which uses microwaves instead of ionizing radiation (X-ray)for breast lesions(BL) detection. Specifically, Mammowave employs a novel technique which generates images by processing very low power (<1 mW) microwaves. The exam takes few minutes per breast and is performed with the patient lying in a comfortable facing down position. Mammowave is safe to be used at any age, in any condition (pregnancy, specific illness) and for unlimited number of times.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: Clinical investigation device class IIa not marked CE Not Applicable

Detailed Description:

The number of participants will be 500 (for all the sites). The Study will be composed of two phases: a preliminary phase to 'optimize the imaging algorithm for each apparatus installed at each centre', where 15 healthy volunteers in each centre will be examined by MammoWave. In the second phase, the remaining people will be enrolled (Breast Lesions pts will be about 70% of total) and examined by MammoWave by the clinical investigator, and results will be compared with the effective diagnosis already obtained by standard clinical methods. BL includes malignant lesions (BC) and benign lesions, and may be palpable or non-palpable lesions. BL includes also isolated clustered microcalcifications.

At the end of the study, in each centre the clinical investigators will compare MammoWave output against the radiologist study output obtained using conventional exams.

In addition, at the end of the study, the MammoWave output will be centrally reviewed in blind by an independent radiologist in order to confirm the data and confirm centrally the comparisons performed locally. The primary goal of the clinical study is to assess Mammowave's ability in BL detection and differentiation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Clinical investigation with Medical Device class IIa
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: A Multicentric, Single Arm, Prospective, Stratified Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection
Estimated Study Start Date : June 1, 2020
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Single arm
All patients perform standard breast screening and also MammoWave exam.
Device: Clinical investigation device class IIa not marked CE
Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.




Primary Outcome Measures :
  1. MammoWave sensitivity (number of 'true positive' results) [ Time Frame: During the procedure ]
    MammoWave sensitivity (number of 'true positive' results) compared to Reference Standard


Secondary Outcome Measures :
  1. MammoWave specificity and sensitivity (against Reference Standard) [ Time Frame: During the baseline ]
    MammoWave specificity and sensitivity (against Reference Standard like Mammography, MRI and/or Echography)

  2. Percentage of correct BL localization in terms of quadrant (against Reference Standard) [ Time Frame: During the baseline ]
    Percentage of correct BL localization in terms of quadrant comparing to Reference Standard like Mammography, MRI and/or Echography

  3. Absolute and rate agreement between different evaluator (i.e. local radiologist versus central) [ Time Frame: Through study completion, an average of 1 year ]
    Absolute and rate agreement between different evaluator local radiologist versus central, in order to avoid mistakes in the MammoWave output.

  4. Sensitivity for each breast density group [ Time Frame: During the baseline ]
    Sensitivity of MammoWave according to different types of breast density groups

  5. Sensitivity for patients which had recent mammography [ Time Frame: During the baseline ]
    Sensitivity for patients which had performed recently mammography exam.

  6. Patient satisfaction questionnaire. [ Time Frame: During the baseline ]

    Patient satisfaction questionnaire output according to their experience performing MammoWave test based on 12 questions:

    n° 2 "Multiple Choice questions"

    YES, NO, explain (with open-ended text area) regarding:

    • The effective execution of MammoWave
    • The willing to promote MammoWave

      n° 5 "5 point Numeric Rating scale" ranging from 1 to 5 (1=Not at all, 5= A lot) regarding the subjective evaluation of MammoWave.

      n° 5 "3 point Numeric Rating scale" ranging from 1 to 3 (1=less, 3= more) regarding the comparative evaluation of MammoWave vs Conventional tests (Mammography, Ultrasound, Magnetic Resonance Imaging).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Women in order to performe breast screening
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed Informed consent Form
  2. Women
  3. Adult ≥18 years old
  4. Having a radiologist study output obtained using conventional exams (such as breast specialist visit and mammography and/or ultrasound and/or magnetic resonance imaging) within the last month.
  5. Patients willing to comply with study protocol and recommendations.
  6. Patients with intact breast skin (i.e. without bleeding lesion, scar).

Exclusion Criteria:

  1. Patients that are enrolled in another clinical study
  2. Patients who belong to any vulnerable group.
  3. Patients with implanted electronics.
  4. Patients who have undergone biopsy less than one week before MammoWave scan
  5. Patients with breast implants
  6. Patients with nipple piercings (unless they are removed before MammoWave exam).
  7. Participation in other studies in the last month before screening
  8. Pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04253366


Contacts
Layout table for location contacts
Contact: Gianluigi Tiberi 0039 3490564302 gianluigi@ubt-tech.com
Contact: Sabatino Tiberi s.tiberi@ubt-tech.com

Locations
Layout table for location information
Italy
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089
Contact: Daniela BERNARDI, Doctor    00393398023851    dnlbernardi@gmail.com   
Azienda Ospedaliera Universitaria S. Martino Di Genova
Genova, Italy, 16132
Contact: Alberto TAGLIAFICO    010/555 3067    Alberto.Tagliafico@unige.it   
Spain
Hospital Virgen de la Salud
Toledo, Spain, 16132
Contact: Cristina ROMERO CASTELLANO, Doctor    0034925269200    cromeroc@gmail.com   
Sponsors and Collaborators
Umbria Bioengineering Technologies

Layout table for additonal information
Responsible Party: Umbria Bioengineering Technologies
ClinicalTrials.gov Identifier: NCT04253366    
Other Study ID Numbers: DE-17-17
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No